Report alleges Lilly pushed off-label use for Zyprexa

12/18/2006 | NYTimes.com

Internal marketing documents from Eli Lilly indicate the drugmaker encouraged doctors to prescribe Zyprexa, a drug for schizophrenia and bipolar disorder, to patients who had neither condition, The New York Times says. The files say Lilly began the Viva Zyprexa campaign in late 2000 and told sales representatives to encourage doctors to prescribe the drug for older patients with dementia symptoms. A Lilly executive says the company has never promoted Zyprexa for off-label use and always shows marketing materials to the FDA.

View Full Article in:

NYTimes.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX